Skip to content

Myopia Control Spectacle Lens Cessation Study

Myopia Control Spectacle Lens Use Cessation Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05893979
Acronym
BIRCH
Enrollment
90
Registered
2023-06-08
Start date
2023-06-23
Completion date
2027-07-31
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Myopia, Myopia, Myopia Progression

Brief summary

To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses. To quantify axial length progression following cessation of use of specific spectacle lenses.

Interventions

Standard Spectacle Lenses

Sponsors

SightGlass Vision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Years to 16 Years
Healthy volunteers
Yes

Inclusion criteria

* Previously a successfully completed participant in the CYPRESS Extension study; * Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day); * Willingness to participate in the trial for up to 12 months without contact lens wear; * The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.

Exclusion criteria

* Known allergy to proparacaine, tetracaine, or tropicamide.

Design outcomes

Primary

MeasureTime frameDescription
Cycloplegic Spherical Equivalent Refraction (cSER)12 monthsChange in cSER

Secondary

MeasureTime frameDescription
Cycloplegic Spherical Equivalent Refraction (cSER)6 monthsChange in cSER
Axial Length (AL)12 monthsChange in AL

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026